Surrey Heartlands

Joint Formulary & PAD

Adalimumab - Psoriasis

You are here : Home > Formulary Search > Adalimumab - Psoriasis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Not Specified
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :

Documentation

Guidelines (Local)
Psoriasis - High cost immunomodulator treatment pathway - October 23.pdf
NICE Technology Appraisal
NICE TA146 - Adalimumab for treating Psoriasis
Webpage
Guidance on the licensing of biosimilar products -MHRA - updated November 2022

PAD Profile

ChemicalSubstance :
Adalimumab
Indication :
Psoriasis
Group Name :
Keywords :
Biologic, NICE, immunosuppressant, Cytokine modulator, TNF Alpha Inhibitor, DMARD, bDmard, Disease modulating, Dermatology, biosimilar
Brand Names Include :
Humira, Hyrimoz, Imraldi, Amgevita, Hulio, Yuflyma, Idacio
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Other Indications

Below are listed other indications that Adalimumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Psoriasis.

Committee Recommendations (3)

04 Oct 23 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated high cost immunomodulator psoriasis treatment pathway.

02 Dec 20 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Psoriasis High Cost immunomodulator Drug Treatment Pathway. 

The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines. The agreed process and associated documentation is saved here https://surreyccg.res-systems.net/PAD/Search/DrugConditionProfile/6549

08 Jul 19 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. 

Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.